Laboratory Assay in Determining Cancer Resistance in Patients With Metastatic Cancer and in Healthy Participants

Study Overview
=================
Brief Summary
-----------------
RATIONALE: Studying samples of blood and tissue in the laboratory from patients with cancer and from healthy participants may help doctors learn more about cancer. PURPOSE: This laboratory study is looking at an assay in determining cancer resistance in patients with metastatic cancer and in healthy participants.

Detailed Description
-----------------
OBJECTIVES: Optimize and standardize the in vitro cell kill assay using human white blood cells and human cancer cell lines from patients with metastatic cancer and from healthy participants. Determine the results of the in vitro cell kill assay in patients with metastatic cancer and in healthy participants with no history of cancer. OUTLINE: This is a pilot study. Peripheral blood is obtained from healthy participants and from cancer patients. Tissue is collected from archived samples. White blood cells are obtained from tissue and blood samples and are assessed by the in vitro cell kill assay. PROJECTED ACCRUAL: A total of 24 patients and 24 healthy participants will be accrued for this study.

Official Title
-----------------
Pilot Study of Cancer Resistance in Humans

Conditions
-----------------
Cancer

Intervention / Treatment
-----------------
* Other: immunological diagnostic method
* Other: physiologic testing


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: -Meets 1 of the following criteria: Diagnosis of metastatic cancer including, but not limited to, any of the following: Stage IV non-small cell lung cancer Extensive-stage small cell lung cancer Metastatic testicular cancer Stage IV breast carcinoma Stage III or IV ovarian carcinoma Stage IV endometrial carcinoma Stage IV prostate carcinoma Stage IV colorectal or pancreatic cancer Stage IV renal cancer Stage III or IV non-Hodgkin's lymphoma Stage IV bladder cancer Stage III multiple myeloma (Salmon-Durie staging) Metastatic melanoma Metastatic sarcoma Healthy participant, meeting the following criteria: No prior cancer Over 50 years of age Exclusion Criteria: Serious medical or psychiatric condition that would preclude study compliance Chemotherapy or radiotherapy within the past 3 months (patient) Prior immunosuppressive therapy or radiotherapy for any disease (healthy participant)

Ages Eligible for Study
-----------------
Maximum Age: 120 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: immunological diagnostic method|nan|
|Other: physiologic testing|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cell killing ability (positive or negative) |  | Day 180 | 
| Percentage of cells killed |  | Day 180 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
stage IV bladder cancer, stage IV colon cancer, stage IV non-small cell lung cancer, stage IV pancreatic cancer, stage IV rectal cancer, stage IV renal cell cancer, stage IV melanoma, stage III multiple myeloma, extensive stage small cell lung cancer, stage IV adult soft tissue sarcoma, stage III malignant testicular germ cell tumor, stage IV breast cancer, stage IV ovarian epithelial cancer, stage IV prostate cancer, stage IV endometrial carcinoma, unspecified adult solid tumor, protocol specific, metastatic osteosarcoma, stage IV uterine sarcoma, stage III ovarian epithelial cancer, ovarian sarcoma, stage IV adult Burkitt lymphoma, stage III adult diffuse large cell lymphoma, stage III adult diffuse small cleaved cell lymphoma, stage IV adult diffuse large cell lymphoma, stage IV adult diffuse mixed cell lymphoma, stage IV adult diffuse small cleaved cell lymphoma, stage III adult Burkitt lymphoma, stage III adult immunoblastic large cell lymphoma, stage IV adult immunoblastic large cell lymphoma, stage III adult lymphoblastic lymphoma, stage IV adult lymphoblastic lymphoma, stage IV grade 1 follicular lymphoma, stage IV grade 2 follicular lymphoma, stage IV grade 3 follicular lymphoma, stage III mantle cell lymphoma, stage IV mantle cell lymphoma, extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue, nodal marginal zone B-cell lymphoma, splenic marginal zone lymphoma, stage III marginal zone lymphoma, stage IV marginal zone lymphoma, stage III small lymphocytic lymphoma, stage IV small lymphocytic lymphoma, stage III mycosis fungoides/Sezary syndrome, stage IV mycosis fungoides/Sezary syndrome, cutaneous B-cell non-Hodgkin lymphoma, stage III cutaneous T-cell non-Hodgkin lymphoma, stage IV cutaneous T-cell non-Hodgkin lymphoma, stage III adult T-cell leukemia/lymphoma, stage IV adult T-cell leukemia/lymphoma, anaplastic large cell lymphoma, angioimmunoblastic T-cell lymphoma, adult nasal type extranodal NK/T-cell lymphoma, Waldenstrom macroglobulinemia, adult grade III lymphomatoid granulomatosis, primary central nervous system non-Hodgkin lymphoma, intraocular lymphoma, stage III adult diffuse mixed cell lymphoma